Your browser doesn't support javascript.
loading
[Efficacy of defroxamine- deferiprone on cardiac function of patients with major thalassemia]
NB., Mirbehbahani; B., Nikyar; N., Behnampour; A., Rashidbaghan; M., Kiani; A., Nikyar.
Journal of Gorgan University of Medical Sciences. 2015; 17 (3): 96-100
in Persian | IMEMR | ID: emr-173790
ABSTRACT
Background and

Objective:

Deferoxamin is the current "gold standard" chelator in comparison with new chelators. Combined therapy of Deferiprone and deferoxamin reduces the cardiac iron overload in patients with major talassemia. This study was done to evaluate the effect of defriprone-deferoxamine on heart function in patients with major thalassemia
Subject(s)
Search on Google
Print
XML
Index: IMEMR (Eastern Mediterranean) Main subject: Pyridones / Stroke Volume / Cohort Studies / Deferoxamine / Ferritins / Heart Function Tests Type of study: Incidence study Limits: Humans Language: Persian Journal: J. Gorgan Univ. Med. Sci. Year: 2015

Similar

MEDLINE
LILACS
LIS
Search on Google
Print
XML
Index: IMEMR (Eastern Mediterranean) Main subject: Pyridones / Stroke Volume / Cohort Studies / Deferoxamine / Ferritins / Heart Function Tests Type of study: Incidence study Limits: Humans Language: Persian Journal: J. Gorgan Univ. Med. Sci. Year: 2015